ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

被引：31

作者：

Jackson, Evangeline R. ^{[1
,2
]}

Duchatel, Ryan J. ^{[1
,2
]}

Staudt, Dilana E. ^{[1
,2
]}

Persson, Mika L. ^{[1
,2
]}

Mannan, Abdul ^{[1
,2
]}

Yadavilli, Sridevi ^{[3
,4
]}

Parackal, Sarah ^{[5
,6
]}

Game, Shaye ^{[5
,6
]}

Chong, Wai Chin ^{[5
,6
]}

Jayasekara, W. Samantha N. ^{[5
,6
]}

Le Grand, Marion ^{[7
]}

Kearney, Padraic S. ^{[1
,2
]}

Douglas, Alicia M. ^{[1
,2
]}

Findlay, Izac J. ^{[1
,2
]}

Germon, Zacary P. ^{[1
,2
]}

McEwen, Holly P. ^{[1
,2
]}

Beitaki, Tyrone S. ^{[1
,2
]}

Patabendige, Adjanie ^{[1
,8
,9
]}

Skerrett-Byrne, David A. ^{[10
,11
]}

Nixon, Brett ^{[10
,11
]}

Smith, Nathan D. ^{[12
]}

Day, Bryan ^{[13
]}

Manoharan, Neevika ^{[14
]}

Nagabushan, Sumanth ^{[14
]}

Hansford, Jordan R. ^{[15
]}

Govender, Dinisha ^{[16
]}

McCowage, Geoff B. ^{[16
]}

Firestein, Ron ^{[5
,6
]}

Howlett, Meegan ^{[17
]}

Endersby, Raelene ^{[17
]}

Gottardo, Nicholas G. ^{[17
,18
]}

Alvaro, Frank ^{[19
]}

Waszak, Sebastian M. ^{[20
,21
,22
]}

Larsen, Martin R. ^{[23
]}

Colino-Sanguino, Yolanda ^{[24
,25
]}

Valdes-Mora, Fatima ^{[24
,25
]}

Rakotomalala, Andria ^{[26
,27
]}

Meignan, Samuel ^{[26
,27
]}

Pasquier, Eddy ^{[7
,28
]}

Andre, Nicolas ^{[7
,28
,29
]}

Hulleman, Esther ^{[30
]}

Eisenstat, David D. ^{[31
,32
]}

Vitanza, Nicholas A. ^{[33
,34
]}

Nazarian, Javad ^{[3
,35
,36
]}

Koschmann, Carl ^{[37
]}

Mueller, Sabine ^{[35
,38
]}

Cain, Jason E. ^{[5
,6
]}

Dun, Matthew D. ^{[1
,2
,39
]}

机构：

[1] Univ Newcastle, Coll Hlth Med & Wellbeing, Sch Biomed Sci & Pharm, Canc Signalling Res Grp, Callaghan, NSW, Australia

[2] Hunter Med Res Inst, Precis Med Res Program, New Lambton Hts, NSW, Australia

[3] Childrens Natl Hosp, Ctr Genet Med Res, Washington, DC USA

[4] Childrens Natl Hosp, Brain Tumor Inst, Washington, DC USA

[5] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia

[6] Monash Univ, Dept Mol & Translat Sci, Clayton, Vic, Australia

[7] Aix Marseille Univ, Inst Paoli Calmettes, Ctr Rech Cancerol Marseille, CNRS,Inserm, Marseille, France

[8] Univ Newcastle, Coll Hlth Med & Wellbeing, Sch Biomed Sci & Pharm, Brain Barriers Grp, Callaghan, NSW, Australia

[9] Edge Hill Univ, Dept Biol, Ormskirk, England

[10] Univ Newcastle, Coll Engn Sci & Environm, Sch Environm & Life Sci, Callaghan, NSW, Australia

[11] Hunter Med Res Inst, Infertil & Reprod Res Program, New Lambton Hts, NSW, Australia

[12] Univ Newcastle, Analyt & Biomol Res Facil Adv Mass Spectrometry U, Callaghan, NSW, Australia

[13] QIMR Berghofer Med Res Inst, Herston, Qld, Australia

[14] Sydney Childrens Hosp, Dept Paediat Oncol, Randwick, NSW, Australia

[15] Univ Adelaide, Womens & Childrens Hosp, South Australia Hlth & Med Res Inst, South Australia ImmunoGen Canc Inst,Michael Rice, Adelaide, Australia

[16] Childrens Hosp Westmead, Dept Oncol, Westmead, NSW, Australia

[17] Univ Western Australia, Telethon Kids Inst, Telethon Kids Canc Ctr, Brain Tumor Res Program, Perth, Australia

[18] Perth Childrens Hosp, Dept Pediat & Adolescent Oncol & Hematol, Perth, Australia

[19] John Hunter Childrens Hosp, New Lambton Hts, NSW, Australia

[20] Univ Oslo, Ctr Mol Med Norway NCMM, Nord EMBL Partnership, Oslo, Norway

[21] Oslo Univ Hosp, Oslo, Norway

[22] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[23] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark

[24] Childrens Canc Inst, Canc Epigenet Biol & Therapeut, Precis Med Theme, Sydney, NSW, Australia

[25] Univ NSW, Sch Womens & Childrens Hlth, Sydney, NSW, Australia

[26] Ctr Oscar Lambret, Tumorigenesis & Resistance Treatment Unit, Lille, France

[27] Univ Lille, Canc Heterogene Plast & Resistance Therapies, CANTHER, CHU Lille,CNRS,Inserm,UMR9020,U1277, Lille, France

[28] Metron Global Hlth Initiat, Marseille, France

[29] La Timone Childrens Hosp, AP HM, Dept Pediat Oncol, Marseille, France

[30] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[31] Royal Childrens Hosp Melbourne, Childrens Canc Ctr, Parkville, Vic, Australia

[32] Univ Melbourne, Murdoch Childrens Res Inst, Dept Paediat, Neurooncol Lab, Parkville, Vic, Australia

[33] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA

[34] Seattle Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA USA

[35] Univ Childrens Hosp Zurich, Dept Pediat, Zurich, Switzerland

[36] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[37] Univ Michigan, Dept Pediat, Div Pediat Hematol Oncol, Ann Arbor, MI USA

[38] Univ Calif San Francisco, Dept Neurol Neurosurg & Pediat, San Francisco, CA USA

[39] Mark Hughes Fdn Ctr Brain Canc Res, Coll Hlth Med & Wellbeing, Paediat Program, Callaghan, NSW, Australia

来源：

CANCER RESEARCH | 2023年 / 83卷 / 14期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

PEDIATRIC HIGH-GRADE; H3.3K27M MUTATION; HISTONE H3.3; GROWTH; INHIBITORS; SURVIVAL; GDC-0084;

D O I：

10.1158/0008-5472.CAN-23-0186

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

◥ Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9 to 11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG. However, further work is needed to identify the mechanisms of response of DIPGs to ONC201 treatment and to determine whether recurring genomic features influence response. Using a systems-biological approach, we showed that ONC201 elicits potent agonism of the mitochondrial protease ClpP to drive proteolysis of electron transport chain and tricarboxylic acid cycle proteins. DIPGs harboring PIK3CA mutations showed increased sensitivity to ONC201, whereas those harboring TP53 mutations were more resistant. Metabolic adaptation and reduced sensitivity to ONC201 was promoted by redox-activated PI3K/Akt signaling, which could be counteracted using the brain penetrant PI3K/Akt inhibitor, paxalisib. Together, these discoveries coupled with the powerful anti-DIPG/DMG pharmacokinetic and pharmacodynamic properties of ONC201 and paxalisib have provided the rationale for the ongoing DIPG/DMG phase II combination clinical trial NCT05009992. Significance: PI3K/Akt signaling promotes metabolic adaptation to ONC201-mediated disruption of mitochondrial energy homeo-stasis in diffuse intrinsic pontine glioma, highlighting the utility of a combination treatment strategy using ONC201 and the PI3K/Akt inhibitor paxalisib.

引用

页码：2421 / 2437

页数：17

共 50 条

[31] PRECLINICAL AND CASE STUDY RESULTS UNDERPINNING THE PHASE II CLINICAL TRIAL TESTING THE COMBINATION OF ONC201 AND PAXALISIB FOR THE TREATMENT OF PATIENTS WITH DIFFUSE MIDLINE GLIOMA (NCT05009992)
Dun, Matthew D.
Jackson, Evangeline R.
Duchatel, Ryan J.
Persson, Mika L.
Mannan, Abdul
Yadavilli, Sridevi
Parackal, Sarah
Game, Shaye
Chong, Wai Chin
Jayasekara, Samantha
Le Grand, Marion
Kearney, Padraic S.
Douglas, Alicia M.
Findlay, Izac J.
Staudt, Dilana
Germon, Zacary P.
Skerrett-Byrne, David A.
Nixon, Brett
Smith, Nathan D.
Hulleman, Esther
Day, Bryan
McCowage, Geoff B.
Alvaro, Frank
Waszak, Sebastian M.
Larsen, Martin R.
Colino-Sanguino, Yolanda
Valdes-Mora, Fatima
Rakotomalala, Andria
Meignan, Samuel
Pasquier, Eddy
Vitanza, Nicholas A.
Nazarian, Javad
Koschmann, Carl
Cain, Jason
Mueller, Sabine
NEURO-ONCOLOGY, 2022, 24 : 18 - 19
[32] H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics
Rechberger, Julian S. S.
Power, Blake T. T.
Power, Erica A. A.
Nesvick, Cody L. L.
Daniels, David J. J.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (01) : 9 - 17
[33] Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Andrew S. Chi
Rohinton S. Tarapore
Matthew D. Hall
Nicole Shonka
Sharon Gardner
Yoshie Umemura
Ashley Sumrall
Ziad Khatib
Sabine Mueller
Cassie Kline
Wafik Zaky
Soumen Khatua
Shiao-Pei Weathers
Yazmin Odia
Toba N. Niazi
Doured Daghistani
Irene Cherrick
David Korones
Matthias A. Karajannis
Xiao-Tang Kong
Jane Minturn
Angela Waanders
Isabel Arillaga-Romany
Tracy Batchelor
Patrick Y. Wen
Krystal Merdinger
Lee Schalop
Martin Stogniew
Joshua E. Allen
Wolfgang Oster
Minesh P. Mehta
Journal of Neuro-Oncology, 2019, 145 : 97 - 105
[34] H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
Gestrich, Catherine
Grieco, Kristina
Lidov, Hart
Ligon, Keith
Santagata, Sandro
Yeo, Kee
Alexandrescu, Sanda
Meredith, David
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2022, 81 (06): : 441 - 441
[35] Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Chi, Andrew S.
Tarapore, Rohinton S.
Hall, Matthew D.
Shonka, Nicole
Gardner, Sharon
Umemura, Yoshie
Sumrall, Ashley
Khatib, Ziad
Mueller, Sabine
Kline, Cassie
Zaky, Wafik
Khatua, Soumen
Weathers, Shiao-Pei
Odia, Yazmin
Niazi, Toba N.
Daghistani, Doured
Cherrick, Irene
Korones, David
Karajannis, Matthias A.
Kong, Xiao-Tang
Minturn, Jane
Waanders, Angela
Arillaga-Romany, Isabel
Batchelor, Tracy
Wen, Patrick Y.
Merdinger, Krystal
Schalop, Lee
Stogniew, Martin
Allen, Joshua E.
Oster, Wolfgang
Mehta, Minesh P.
JOURNAL OF NEURO-ONCOLOGY, 2019, 145 (01) : 97 - 105
[36] Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Trabulo, C. F. P.
Cabral, S. C.
Antao, D.
Costa, J.
Fernandes, M.
Passos Marques, J.
Marques, J.
Azevedo, A.
Nunes, J.
Costa, I.
Marques, A. R.
Serpa, A.
Roque, L.
Mafra, M.
Matos Pina, I. M.
Salgado, D.
ANNALS OF ONCOLOGY, 2023, 34 : S409 - S409
[37] COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992).
Jackson, Evangeline
Duchatel, Ryan
Staudt, Dilana
Persson, Mika
Mannan, Abdul
Yadavilli, Sridevi
Parackal, Sarah
Game, Shaye
Chong, Wai Chin
Jayasekara, W. Samantha
Le Grand, Marion
Kearney, Padraic
Douglas, Alicia
Findlay, Izac
Germon, Zacary
McEwen, Holly
Beitaki, Tyrone
Patabendige, Adjanie
Skerrett-Byrne, David
Nixon, Brett
Smith, Nathan
Day, Bryan
Manoharan, Neevika
Nagabushan, Sumanth
Hansford, Jordan
Govender, Dinisher
McCowage, Geoffrey
Firestein, Ron
Howlett, Meegan
Endersby, Raelene
Gottardo, Nicholas
Alvaro, Frank
Waszak, Sebastian
Larsen, Martin
Sanguino, Yolanda Colino
Valdes-Mora, Fatima
Rakotomalala, Andria
Meignan, Samuel
Pasquier, Eddy
Andre, Nicolas
Hulleman, Esther
Eisenstat, David
Vitanza, Nicholas
Nazarian, Javad
Koschmann, Carl
Mueller, Sabine
Cain, Jason
Dun, Matthew
NEURO-ONCOLOGY, 2023, 25
[38] DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED: A COMPREHENSIVE CLINICAL AND BIOMOLECULAR LANDSCAPE OF THE NON-PONTINE TUMORS
Mariet, Cassandra
Tauziede-Espariat, Arnault
Auffret, Lucie
Ajlil, Yassine
Roux, Alexandre
Pallud, Johan
Palfi, Stephane
Metais, Alice
Beccaria, Kevin
Blauwblomme, Thomas
Puget, Stephanie
Sanson, Marc
Peloux, Marie
Richard, Juliette
Thalhammer, Julian
Carvalho, Alice
Puiseux, Chloe
Pereira, Victor
de Carli, Emilie
Lesieur, Thomas
Rouger, Jeremie
Page, Philipe
Doz, Francois
Bourdeaut, Franck
Dufour, Christelle
Abou, Samuel
Guerrini-Rousseau, Lea
Dhermain, Frederic
Bolle, Stephanie
Varlet, Pascale
Grill, Jacques
Castel, David
NEURO-ONCOLOGY, 2024, 26
[39] ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?
Hansford, Jordan R.
Manoharan, Neevika
Bouche, Gauthier
Ramaswamy, Vijay
Jabado, Nada
Bouffet, Eric
EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (04) : 321 - 325
[40] Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review
Watanabe, Gina
Wong, Jennifer Manyu
Estes, Bradley
Khan, Mohammad Faizan
Ogasawara, Christian
Umana, Giuseppe E.
Martin, Allan R.
Bloch, Orin
Palmisciano, Paolo
JOURNAL OF NEURO-ONCOLOGY, 2024, 166 (03) : 379 - 394

← 1 2 3 4 5 →